Inverse association between plasma homocysteine, sulphonylurea exposure and physical activity: A community-based sample of type 2 diabetes patients in the Skaraborg hypertension and diabetes project

Diabetes, Obesity and Metabolism

Volumn 7, Issue 4, 2005, Pages 421-429

  Hellgren, M ^a,b   Melander, A ^c,d   Ostgren C J ^d   Rastam L ^d   Lindblad, Ulf ^b,d  

^a Hentorp Health Care Centre   (Sweden)

^b Skaraborgs Institutet   (Sweden)

^c Network for Pharmacoepidemiology Foundation   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Homocysteine; Kidney function; Physical activity; Sulphonylurea; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; CREATININE; FOLIC ACID; HEMOGLOBIN A1C; HOMOCYSTEINE; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIET THERAPY; DRUG EXPOSURE; FEMALE; FOLIC ACID BLOOD LEVEL; HEALTH PROGRAM; HEART PROTECTION; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; POPULATION RESEARCH; PRIMARY MEDICAL CARE; PUBLIC HEALTH; SEX RATIO; STATISTICAL DISTRIBUTION; SWEDEN;

EID: 21444448091     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2004.00431.x     Document Type: Article

References (42)

1. Knekt P, Alfthan G, Aromaa A et al. Homocysteine and major coronary heart events: a prospective population study amongst women. J Intern Med 2001; 249: 461-465.
2. van Guldener C, Stam F, Stehouwer CD. Homocysteine metabolism in renal failure. Kidney Int Suppl 2001; 78: S234-S237.
3. Nygard O, Vollset SE, Refsum H et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocystein Study. JAMA 1995; 274: 1526-1533.
4. Coull BM, Malinow MR, Beamer N et al. Elevated plasma homocysteine concentration as a possible independent risk factor for stroke. Stroke 1990; 21: 572-576.
5. Lewerin C, Nilsson-Ehle H, Matousek M, Lindstedt G, Steen B. Reduction of plasma homocysteine and serum methylmalonate concentrations in apparently healthy elderly subjects after treatment with folic acid, vitamin B12 and vitamin B6: a randomised trial. Eur J Nutr 2003; 57: 1426-1436.
6. Nygård O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocystein Study. Am J Clin Nutr 1998; 67: 263-270.
7. Rasmussen LB, Ovesen L, Bulow I, Knudsen N, Laurberg P, Perrild H. Folate intake, lifestyle factors, and homocysteine concentrations in younger and older women. Am J Clin Nutr 2000; 72: 1156-1163.
8. Mennen LI, de Courcy GP, Guilland JC, Ducros D. Homocysteine, cardiovascular risk factors, and habitual diet in the French supplementation with antioxidant vitamins and minerals study. Am J Clin Nutr 2002; 76: 1279-1289.
9. Drzeweski J, Czuprynisk L, Chwatko G, Bald E. Hyper-homocysteinemia in poorly controlled type 2 diabetes patients. Diabetes Nutr Metab 2000; 13: 319-324.
10. Passaro A, Calzoni F, Volpato S et al. Effect of metabolic control on homocysteine levels in type 2 diabetic patients: a 3-year follow-up. J Intern Med 2003; 254: 264-271.
11. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-1050.
12. Abdella NA, Mojiminiyi OA, Akanji AO, Moussa MA. Associations of plasma homocysteine concentration in subjects with type 2 diabetes mellitus. Acta Diabetologica 2002; 39: 183-190.
13. Mazza A, Guigliano D, Matti C et al. Glycemia, MTHFR genotype and low homocysteine in uncomplicated type 2 diabetic patients. Arterosclerosis 2000; 149: 223-224.
14. Pixa A, Pietzsch J, Julius U, Menschikowski M, Hanefeld M. Impaired glucose tolerance (IGT) is not associated with disturbed homocysteine metabolism. Amino Acids 2000; 18: 289-298.
15. Wulffele MG, Kooy A, Lehert P et al. Effects of short term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2003; 254: 455-463.
16. Carlsen SM, Folling J, Grill V, Bjerne KS, Schneede J, Refsum H. Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease. Scand J Clin Lab Invest 1997; 57: 521-527.
17. de Bree A, Verschuren WM, Blom HJ, Kromhout D. Lifestyle factors and plasma homocysteine concentrations in a general population sample. Am J Epidemiol 2001; 154: 150-154.
18. Hoogeven EK, Kostense PJ, Jakobs C, Bouter LM, Heine RJ, Stehouwer CDA. Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus? J Intern Med 1997; 242: 389-394.
19. Derosa G, Mugellini A, Ciccarelli L, Crescenzi, G, Fogari R. Comparision between repaglinide and glimeperid in patients with type 2 diabetes mellitus: a one year, randomized, double blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther 2003; 25: 472-484.
20. Gregorio F, Ambrosit F, Manfrini S et al. Poorly controlled elderly type 2 diabetic patients: the effect of increasing sulphonylurea dosages or adding metformin. Diabet Med 1999; 16: 1016-1024.
21. Araki A, Sako Y, Ito H. Plasma homocysteine concentrations in Japanese patients with non-insulin-dependent diabetes mellitus: effect of parental methylcobalamin treatment. Atherosclerosis 1993; 103: 149-157.
22. Bøg-Hansen E, Lindblad U, Bengtsson K, Ranstam J, Melander A, Råstam L. Risk factor clustering in patients with hypertension and non-insulin dependent diabetes mellitus. The Skaraborg Hypertension and diabetes project. J Intern Med 1998; 243: 223-232.
23. Ostgren CJ, Lindblad U, Bøg-Hansen E, Ranstam J, Melander A, Rastam L. Differences in treatment and metabolic abnormalities between normo- and hypertensive patients with type 2 diabetes: the Skaraborg Hypertension and diabetes project. Diabetes Obes Metab 1999; 1: 105-112.
24. Bengtsson AK, Orho M, Lindblad U et al. Polymorphisms in the angiotension converting enzyme but not in the angiotensinogen gene is associated with hypertension and type 2 diabetes. The Skaraborg Hypertension and Diabetes project. J Hypertens 1999; 17: 1569-1575.
25. Ostgren CJ, Lindblad U, Melander A, Melander O, Groop L, Rastam L. Peroxisome proliferator-activated receptor-gammaPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: Skaraborg hypertension and diabetes project. J Hypertens 2003; 21: 1657-1662.
26. Ostgren CJ, Lindblad U, Ranstam J, Melander A, Rastam L. Associations between smoking and Beta-cell function in a non-hypertensive and non-diabetic population. Diabet Med 2000; 17: 445-450.
27. Rastam L, Sjonell G. Measurement of blood pressure with Tricuff. Lancet 1991; 337 (8750): 1162.
28. Andersen L, Dinesen B, Jörgensen PN, Poulsen F, Röder ME. Enzyme immunoassey for human insulin in serum or plasma. Clin Chem 1993; 38: 578-582.
29. Fiskestrand T, Refsum H, Kvalheim G, Ueland PM. Homocystein and other thiols in plasma and urine: automated determination and sample stability. Clin Chem 1993; 39: 263-271.
30. Bayer Immuno system. System clinical method. RBC Folate publication DA4-1217M95 December 1995.
31. World Health organisation Expert Committee. Diabetes Mellitus. Technical report Series no. 742. Geneva: WHO, 1985.
32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
33. National board of Health, Welfare drug Information Committee. Treatment of Mild Hypertension. Stockholm: Sweden, 1987.
34. Haffner S, Miettinen H, Stern M. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997; 20: 1087-1092.
35. Fonseca VA, Mudaliar S, Schmidt B, Fink LM, Kern PA, Henry RR. Plasma homocysteine concentrations are regulated by acute hyperinsulinemi in nondiabetic but not type 2 diabetic subjects. Metabolism 1998; 47: 686-689.
36. Dicker-Brown A, Fonseca VA, Fink LM, Kern PA. The effect of glucose and insulin on the activity of methylene tetrahydrofolate reductase and cystationine-β-synthase: studies in hepatocytes. Atherosclerosis 2001; 158: 297-301.
37. Meigs JB, Jacques PF, Selhub J, Singer DE. Fasting plasma homocysteine levels in the insulin resistance syndrome. Diabetes Care 2001; 24: 1403-1410.
38. Tanasescu M, Leizmann MF, Rimm EB, Willett WC, Stampfer MJ. Exercise type and intensity in relation to coronary heart disease in men. JAMA 2003; 288: 1994-2000.
39. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
40. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
41. Baily CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-579.
42. Knowler WC, Sartor G, Melander A, Scherstén B. Glucose tolerance and mortality, including a substudy of tolbutamide treatment. Diabetologia 1997; 40: 680-686.